
 
 
 
 
 
 
 
 
 WHAT IS CLAIMED IS: 
 
 1. A chimeric antigen for eliciting an immune response comprising an immune response domain and a target binding domain, wherein the target binding domain comprises an antibody fragment. 
 
 
 2. The chimeric antigen of claim 1, wherein the antibody fragment is a xenotypic antibody fragment. 
 
 
 3. The chimeric antigen of claim 1 , wherein the antibody fragment is not a . xenotypic antibody fragment. 
 
 
 4. The chimeric antigen of claim 1, wherein the chimeric antigen comprises more than one immune response domain. 
 
 
 5. The chimeric antigen of claim 1, wherein the immune response domain comprises at least one antigenic portion of a protein selected from the group consisting a HBV protein, a DHBV protein and a HCV protein. 
 
 
 6. The chimeric antigen of claim 5, wherein the immune response domain comprises at least one antigenic portion of a HBV protein selected from the group consisting of HBV S1/S2, HBV S1/S2/S, HBV Core, HBV Core ctm and HBV polymerase. 
 
 
 7. The chimeric antigen of claim 5, wherein the immune response domain comprises at least one antigenic portion of a DHBV protein selected from the group consisting of DHBV PreS/S, DHBV PreS, DHBV Core and DHBV polymerase. 
 
 
 8. The chimeric antigen of claim 5, wherein the immune response domain comprises at least one antigenic portion of a HCV protein selected from the group consisting of HCV Core (1-191), HCV Core (1-177), HCV E1-E2, HCV El, HCV E2, 
 HCV NS3, HCV NS5A and HCV NS4A. 
 
 
 9. The chimeric antigen of any of claims 1-8, wherein the immune response domain further comprises a 6xHis tag fused to the protein. 
 59   
 
 
 10. The chimeric antigen of any of claims 1 -9 wherein the immune response domain comprises one or more antigenic portions of a protein from HPV, HIV, HSV, an obligate intracellular parasite or a cancer antigen. 
 
 
 11. The chimeric antigen of any of claims 1-10, wherein the target binding domain is capable of binding to an antigen presenting cell. 
 
 
 12. The chimeric antigen of any of claims 1-11, wherein the antibody fragment comprises an immunoglobulin heavy chain fragment. 
 
 
 13. The chimeric antigen of claim 12, wherein the immunoglobulin heavy chain fragment comprises a hinge region. 
 
 
 14. The chimeric antigen of claim 12, wherein the chimeric antigen further comprises amino acids, VDKKI (SEQ ID NO: 2). 
 
 
 15. The chimeric antigen of claim 12, wherein the immunoglobulin heavy chain fragment comprises C H 2 and C H 3 domains. 
 
 
 16. The chimeric antigen of any of claims 1-15, wherein the antibody fragment is a Fc fragment. 
 
 
 17. The chimeric antigen of any of claims 1-15, wherein the antibody fragment comprises a portion of a C H I region and an antibody hinge region. 
 
 
 18. The chimeric antigen of any of claims 1-17, further comprising a linker for linking the immune response domain and the target binding domain. 
 
 
 19. The chimeric antigen of claim 18, wherein the linker is a covalent peptide linkage. 
 
 
 20. The chimeric antigen of claim 19, wherein the peptide linkage comprises the sequence SRPQGGGS or VRPQGGGS ( SEQ ID NO: 1). 
 
 
 21. The chimeric antigen of claim 18, wherein the linker is selected from the group consisting of leucine zippers and biotin/avidin. 
 60   
 
 
 22. The chimeric antigen of any of claims 1-21, wherein the chimeric antigen is mannose glycosylated. 
 
 
 23. The chimeric antigen of claim 22, wherein the immune response domain is mannose glycosylated. 
 
 
 24. The chimeric antigen of claim 22, wherein the target binding domain is mannose glycosylated. 
 
 
 25. The chimeric antigen of claim 22, wherein the chimeric antigen is pauci mannose glycosylated. 
 
 
 26. The chimeric antigen of claim 22, wherein the chimeric antigen is high mannose glycosylated. 
 
 
 27. The chimeric antigen of claim 1, wherein the target binding domain comprises amino acid sequences SRPQGGGS (SEQ ID NO: 1), VDKKI (SEQ ID NO: 2) and C H 2 and C H 3 domains of the murine immunoglobulin heavy chain constant region. 
 
 
 28. The chimeric antigen of any of claims 1-27, which elicits a multi-epitopic response. 
 
 
 29. The chimeric antigen of claim 1, which elicits an immune response to at least one epitope of the immune response domain. 
 
 
 30. The chimeric antigen of any of claims 1-29, which elicits a humoral immune response. 
 
 
 31. The chimeric antigen of any of claims 1 -29, which elicits a cellular immune response. 
 
 
 32. The chimeric antigen of any of claims 1-29, which elicits a Thl immune response, a Th2 immune response, a CTL response, or a combination thereof. 
 
 
 33. A method of enhancing antigen presentation in an antigen presenting cell comprising contacting the antigen presenting cell with a composition comprising a chimeric antigen of any of claims 1-32. 
 61   
 
 
 34. The method of claim 33, wherein the antigen presenting cell is a dendritic cell. 
 
 
 35. The method of claim 34, wherein the method enhances antigen presentation of more than one epitope. 
 
 
 36. The method of claim 34, wherein the method enhances antigen presentation of at least one epitope of the immune response domain. 
 
 
 37. A method of activating an antigen presenting cell comprising contacting the antigen presenting cell with a chimeric antigen of any of claims 1-32. 
 
 
 38. The method of claim 33 or 37, wherein the contacting takes place ex vivo. 
 
 
 39. The method of claim 33 or 37, wherein the contacting takes places in vivo. 
 
 
 40. The method of claim 39, wherein the contacting takes place in a human. 
 
 
 41. A method of eliciting an immune response comprising administering to a subject a composition comprising a chimeric antigen of any of claims 1-32. 
 
 
 42. A method of breaking tolerance comprising contacting an antigen presenting cell with a chimeric antigen of any of claims 1-32. 
 
 
 43. A method for treating an immune-treatable condition comprising administering, to a subject in need thereob a chimeric antigen of any of claims 1-32. 
 
 
 44. The method according to any of claims 41-43, wherein administration of the immune response domain alone does not elicit an immune response. 
 
 
 45. The method according to any of claims 41-43, wherein administration of the chimeric antigen elicits a greater immune response than administration of the immune response domain alone. 
 
 
 46. The method of claim 45, wherein the immune response is measured by the amount of antigen-specific antibody present in the subject. 
 
 
 47. The method of claim 45, wherein the immune response is measured by the amount of interferon-Î³ secreted by T cells in response to being exposed to antigen presenting cell loaded with the chimeric antigen or immune response domain alone. 62   
 
 
 48. The method of claim 45, wherein the immune response is measure by the amount of antigen-specific CD8 +  T cells elicited in response to being exposed to antigen presenting cell loaded with the chimeric antigen or immune response domain alone. 
 
 
 49. The method according to any of claims 41-43, wherein the subject has an infection or a cancer. 
 
 
 50. The method of claim 49, wherein the infection is a viral infection or a parasitic infection. 
 
 
 51. The method of claim 50, wherein the infection is a chronic viral infection. 
 
 
 52. The method of claim 51 , wherein the chronic viral infection is a chronic hepatitis B viral infection or a chronic hepatitis C viral infection, a chronic human papilloma viral infection, a chronic human immunodeficiency viral infection, or a chronic herpes simplex viral infection . 
 
 
 53. The method of claim 52, wherein the infection is a hepatitis B viral infection and the immune response domain comprises at least one antigenic portion of a protein selected from the group consisting of HBV Core protein, a HBV S protein, a HBV SI protein and a HBV S2 protein and combinations thereof. 
 
 
 54. The method of claim 52, wherein the infection is a hepatitis C viral infection and the immune response domain comprises at least one antigenic portion of a protein selected from the group consisting of a HCV core (1-191) protein, a HCV Core (1- 177) protein, a HCV El protein, a HCV E2 protein, a HCV E1-E2 protein, a HCV NS3 protein, a HCV NS5A protein and combinations thereof. 
 
 
 55. A method of vaccinating a subject against a viral infection comprising administering to the subject, a chimeric antigen of any of claims 1-32. 
 
 
 56. The method of claim 55, wherein the subject is therapeutically vaccinated against an existing viral infection. 
 
 
 57. The method of claim 55, wherein the subject is prophylactically vaccinated against a viral infection. 63   
 
 
 58. The method of claim 55, wherein the subject develops an immune response to more than one epitope of the chimeric antigen. 
 
 
 59. The method of claim 58, wherein the subject develops an immune response to more than one epitope of the immune response domain. 
 
 
 60. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a chimeric antigen of any of claims 1-32. 
 
 
 61. The pharmaceutical composition of claim 60, wherein the pharmaceutical composition is formulated for parenteral administration. 
 
 
 62. The pharmaceutical composition of claim 60, wherein the pharmaceutical composition is formulated for transdermal, intradermab intravenous, subcutaneous, intramuscular, nasal, pulmonary or oral administration. 
 
 
 63. An article of manufacture comprising a chimeric antigen according to any of claims 1-32 and instructions for administering the chimeric antigen to a subject in need thereof. 
 
 
 64. A method of producing a chimeric antigen comprising: (a) providing a microorganism or cell line, which comprises a polynucleotide that encodes a chimeric antigen according to any of claims 1-32; and (b) culturing said microorganism or cell line under conditions whereby the chimeric antigen is expressed. 
 
 
 65. The method of claim 64, wherein the microorganism or cell line is a eukaryotic microorganism or cell line. 
 
 
 66. The method of claim 65, wherein the microorganism or cell line is a yeast, a plant cell line or an insect cell line. 
 
 
 67. The method of claim 64, wherein the chimeric antigen is post-translationally modified to comprise a mannose glycosylation. 
 
 
 68. A polynucleotide encoding a chimeric antigen, said polynucleotide comprising a first polynucleotide portion encoding an immune response domain and a second 
 64  polynucleotide portion encoding a target binding domain, wherein the target binding domain comprises an antibody fragment. 
 
 
 69. The polynucleotide of claim 68, wherein the immune response domain comprises at least one antigenic portion of a viral protein. 
 
 
 70. The polynucleotide of claim 69, wherein the viral protein is a HBV protein or a HCV protein. 
 
 
 71. The polynucleotide of claim 68, wherein the antibody fragment is a xenotypic fragment. 
 
 
 72. The polynucleotide of claim 68, wherein the antibody fragment is not a xenotypic fragment. 
 
 
 73. The polynucleotide of claim 68, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of nucleotides 1 to 1326 of 
 SEQ ID NO: 26, nucleotides 1 to 2004 of SEQ ID NO 28, nucleotides 1 to 1350 of SEQ ID NO: 30, nucleotides 1 to 1293 of SEQ ID NO 32, nucleotides 1 to 1794 of SEQ ID NO: 34, nucleotides 1 to 1581 of SEQ ID NO 36, nucleotides 1 to 1389 of SEQ ID NO: 38, nucleotides 1 to 1347 of SEQ ID NO 40, nucleotides 1 to 2157 of SEQ ID NO: 42, nucleotides 1 to 1395 of SEQ ID NO 44, nucleotides 1 to 1905 of 
 SEQ ID NO: 46 and nucleotides 1 to 2484 of SEQ ID NO: 48. 
 
 
 74. The polynucleotide of claim 68, wherein the polynucleotide encodes a chimeric antigen that is at least 90% identical to an entire amino acid sequence selected from the group consisting of amino acids 1 to 442 of SEQ ID NO: 27, amino acids 1 to 668 of SEQ ID NO: 29, amino acids 1 to 450 of SEQ ID NO: 31, amino acids 1 to 431 of SEQ ID NO: 33, amino acids 1 to 598 of SEQ ID NO: 35, amino acids 1 to 527 of SEQ ID NO: 37, amino acids 1 to 463 of SEQ ID NO: 39, amino acids 1 to 449 of SEQ ID NO: 41, amino acids 1 to 719 of SEQ ID NO: 43, amino acids 1 to 465 of SEQ ID NO: 45, amino acids 1 to 635 of SEQ ID NO: 47 and amino acids 1 to 828 of SEQ ID NO: 49. 
 
 
 75. The polynucleotide of claim 68, wherein the polynucleotide selectively hybridizes under stringent conditions to a polynucleotide having a nucleotide 
 65  sequence selected from the group consisting of SEQ ID NO: 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48 
 
 
 76. A microorganism or cell line comprising the polynucleotide of claim 68. 
 
 
 77. A vector comprising the polynucleotide of claim 68. 
 66  
 
 
 
 
 
 
 
 
 
 
